Intellectual Property Law

HB Ad Slot
HB Mobile Ad Slot

Intellectual property applies to many different areas of the legal world. Applying for patents for work-products, by individual employees, trademark laws, copyrights, and how companies leverage their IP asset-rights over employees, are just a few of the many areas the National Law Review covers as it pertains to IP.

Intellectual Property Litigation

Intellectual Property disputes are a complex area of law, often involving deep dives into complex concepts to understand the issues at play. In the United States, the United States Patent and Trademark Office (USPTO/PTO) is the agency involved in registering patents and trademarks.   As part of the USPTO, the Patent Trial and Appeal Board settles patent disputes, using a variety of mechanisms to settle issues related to intellectual property.    Some of the mechanisms include inter partes review, post-grant procedures, and covered business method patent reviews.  Issues related to the America Invents Act are also settled through the PTAB. The National Law Review covers changes to standards held by the USPTO in litigation and other patent issues.  The Trademark Trial and Appeal Board settles disputes related to trademarks, such as an ex parte appeal from the denial of an application for registration by an examining attorney, and an inter partes opposition, cancellation, concurrent use, or interference proceeding.  Other agencies involved in patent disputes are the International Trade Commission (ITC) or the Federal Trade Commission (FTC).  The National Law Review covers patent news as it relates to Supreme Court (SCOTUS) and federal circuit courts’ appeals, as well as general patent litigation and new patent filings.

Intellectual Property in Drug Patents

Legal analysis related to drug patents and pharmaceuticals and the interplay with intellectual property issues are also covered by the National Law Review.   Drug patents, biosimilars, generic top-level domain registration (gTLD), trade secrets, non-compete clauses, and other patent application news are updated on the site regularly. Additionally, tangential issues that impact pharmaceutical companies, such as innovator liability and related litigation, are also analyzed by the legal experts who write for the National Law Review. 

Intellectual Property in an Employment Context

The National Law Review has legal analysis on the intersection between intellectual property rights and employment, and who owns ideas, the Work Made For Hire principle as well resulting litigation. Additionally, legislation such as the Defense of Trade Secrets Act and its impact on workplaces, and ongoing litigation related to the legislation is also covered.

International Intellectual Property

Visitors to the site will oftentimes read about international news as it relates to patent applications in the US, and internationally as well. Pharmaceutical patents in Brazil, medical device patent applications from the United Kingdom, or litigation from the European Union, China, India, and other international sectors, are often covered online. Visitors will find the latest coverage, news, and insights on patent applications and litigation, when visiting the National Law Review, for up-to-date practice-area news.

National Law Review Intellectual Property/Patent Law TwitterFor hourly updates on the latest news about Intellectual Property Law, IP Litigation, Patent Legislation, and more, be sure to follow our IP Law Twitter feed, and sign up for complimentary e-news bulletins.

Recent Intellectual Property, Patent, Trademark & Copyright News

Title
Custom text Organization Sort descending
Aug
18
2015
Sequenom Seeks Rehearing En Banc Foley & Lardner LLP
Jul
19
2022
The Latest Patent Developments in China: What Manufacturers Need to Know Foley & Lardner LLP
Feb
13
2018
When Does An RCE Stop The PTA Clock? Foley & Lardner LLP
Apr
25
2018
Supreme Court Holds That the PTO Cannot Institute Review on Only Some of the Challenged Claims Foley & Lardner LLP
May
22
2018
Patent Related Changes To Bayh-Dole Act Regulations Foley & Lardner LLP
Nov
16
2015
Federal Circuit To Revisit On Sale Bar Triggered By Contract Manufacture Foley & Lardner LLP
Aug
7
2018
Sales Catalog From Dealer Trade Show Qualifies As Printed Publication Foley & Lardner LLP
Dec
17
2015
Federal Circuit Affirms PTAB's IPR Decision Invalidating A Pharmaceutical Patent Foley & Lardner LLP
Sep
18
2018
Federal Circuit Outlines Four Options For Overcoming Obviousness Rejections Based On Routine Optimization Foley & Lardner LLP
May
1
2023
Another Letter From Congress Complaining About Pharmaceutical Patents Foley & Lardner LLP
Dec
30
2015
Use of Priority Denial to Subject Apparent "Pre-AIA" Patents to PGR: Inguran v. Premium Genetics Foley & Lardner LLP
Oct
1
2018
Insurers Must Pay Cost of Defending Case Stemming from Use of Famous Marathoner’s Name Foley & Lardner LLP
May
16
2023
Supreme Court Won’t Hear Skinny Label Case Foley & Lardner LLP
Jan
19
2016
PTAB Denies Challenge Of Abbvie Humira Patents Foley & Lardner LLP
Oct
26
2018
USPTO Announces Proposal To Facilitate Amendments In AIA Challenges Foley & Lardner LLP
Nov
27
2018
District Court Finds PK Targets Of VIMOVO Patents Indefinite Foley & Lardner LLP
Jan
29
2016
Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions Foley & Lardner LLP
Jan
7
2019
New USPTO Guidance on Patent Subject Matter Eligibility Seeks to Standardize Abstract Idea Analysis Foley & Lardner LLP
Feb
11
2016
FDA Panel Shows Strong Support for Remicade Biosimilar Foley & Lardner LLP
Aug
24
2023
Building Distinction in Architectural Trade Dress Foley & Lardner LLP
Mar
26
2019
Federal Circuit Upholds Method Of Treatment Claims Under Vanda And Distinguishes Mayo Foley & Lardner LLP
May
7
2019
Will The Biologic Patent Transparency Act Shrink The Biosimilar Patent Dance Floor? Foley & Lardner LLP
Apr
22
2016
Can Foreign Sales Infringe U.S. Patents? Foley & Lardner LLP
May
5
2016
Are Drug Prices Really Too High? Foley & Lardner LLP
May
9
2016
New USPTO Guidance On Patent Eligibility Of Diagnostic Methods Foley & Lardner LLP
Feb
19
2024
Which Significant USPTO Fee Increases Might We See in 2025? Foley & Lardner LLP
Mar
8
2024
IP Challenges in the Energy Transition [Podcast] Foley & Lardner LLP
Jun
28
2016
Supreme Court Deals Blow To Diagnostic Method Patents, Denies Cert In Sequenom Foley & Lardner LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins